ARS Pharmaceuticals, Inc. Payments to Acquire Debt Securities, Available-for-sale
ARS Pharmaceuticals, Inc. (SPRY) reported Payments to Acquire Debt Securities, Available-for-sale of $0 for the 9-month period ending 2022-09-30, per its 10-Q filed 2022-11-02.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt · last filed 2022-11-02
- ARS Pharmaceuticals, Inc. payments to acquire debt securities, available-for-sale for the quarter ending 2021-12-31 was $25.14M.
- ARS Pharmaceuticals, Inc. payments to acquire debt securities, available-for-sale for fiscal 2021 was $65.11M.
- ARS Pharmaceuticals, Inc. payments to acquire debt securities, available-for-sale for fiscal 2020 was $0.00.
| Period end | Payments to Acquire Debt Securities, Available-for-sale 3 month | Payments to Acquire Debt Securities, Available-for-sale 9 month | Payments to Acquire Debt Securities, Available-for-sale 12 month |
|---|---|---|---|
| 2022-09-30 | $0.00 10-Q · filed 2022-11-02 | ||
| 2021-12-31 | $25.14M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $65.11M 10-K · filed 2022-03-31 | |
| 2021-09-30 | $39.97M 10-Q · filed 2022-11-02 | ||
| 2020-12-31 | $0.00 10-K · filed 2022-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 |